S&CO Inc. Buys New Shares in Alnylam Pharmaceuticals, Inc. $ALNY

S&CO Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, HoldingsChannel reports. The fund purchased 7,400 shares of the biopharmaceutical company’s stock, valued at approximately $2,227,000.

A number of other large investors have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $29,000. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $25,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of Alnylam Pharmaceuticals stock opened at $228.65 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The stock has a market capitalization of $30.60 billion, a P/E ratio of 42.50 and a beta of 0.30. The company has a 50-day simple moving average of $272.86 and a 200 day simple moving average of $301.44. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ALNY. Citigroup cut their target price on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Oppenheimer decreased their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $393.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.